CF101
CF101-201KCS
Phase 3 small_molecule completed
Quick answer
CF101 for Keratoconjunctivitis Sicca is a Phase 3 program (small_molecule) at Can-Fite BioPharma with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Can-Fite BioPharma
- Indication
- Keratoconjunctivitis Sicca
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed